31.07.2013 • NewsAndrew LiverisDede WillamsDow Chemical

Dow Chemical EBITDA up 9% in Q2

U.S. chemical giant Dow Chemical saw adjusted EBITDA gain nearly 9% year-on-year to $ 2.1 billion in Q2 2013, thanks mainly to strong business in the Agricultural Science and Performance Plastics segments. The unusually large adjustment reflects a payment of $2.2 from Petrochemical Industries Company of Kuwait in arbitration over the K-Dow joint venture canceled by Kuwait in 2009. Quarterly sales were flat at $14.6 billion. Led by activities in emerging markets that more than offset a decline in Europe, volume growth averaged 9%, said CEO Andrew Liveris. Prices receded by 2%, due in part to currency translations. 

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

most read

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.